Thioacetamide

Research use only, not for human use.

Thioacetamide is a hepatotoxicant used widely to induce experimental liver lesions, develops hepatocellular necrosis and subsequent inflammation (mainly M1-/M2-macrophages without neutrophil infiltration) in rats.

Thioacetamide is a hepatotoxicant used widely to induce experimental liver lesions, develops hepatocellular necrosis and subsequent inflammation (mainly M1-/M2-macrophages without neutrophil infiltration) in rats.

Thioacetamide (TAA; 0-10000 μM; 24 h; WB-F344 cells) has cytotoxicity in a concentration-dependent manner.Thioacetamide (TAA; 1000 and 10000 μM; 0-24 h; WB-F344 cells) has differentially-expressed genes in the early phases at low (1000 μM) and high (10000 μM) concentrations. Cell Viability AssayCell Line:WB-F344 cells Concentration:0-10000 μM Incubation Time:24 hours Result:Had 20% and 50% cell death at the 1000 and 10000 μM concentrations, respectively.

Thioacetamide (TAA; 100 mg/kg; i.p.; three times weekly) can induce chronic liver fibrosis in male ICR mice.Thioacetamide (200-1200 mg/kg; i.p.; once) induces hepatic encephalopathy model in C57BL/6 mice. Animal Model:Male ICR mice Dosage:100 mg/kg Administration:Intraperitoneal injection; three times weekly for eight weeks Result:Induced chronic liver fibrosis in male ICR mice and resulted in lower body weight, serum cholesterol and triglycerides as well as increased liver size, ALT, AST and LDH values.Animal Model:Male C57BL/6 mice (20-25g, aged 8-12 weeks)Dosage:200, 600, and 1,200 mg/kg Administration:Intraperitoneal injection; once Result:Altered the neuropsychiatric state, motor behavior and reflex and sensory functions.Increased in the glutamate release in the cerebral cortex of Hepatic encephalopathy (HE) mice.

TAA

Others

Other Targets

HIV|IL Receptor|MIP|NF-κB|NO|TNF-α

——

——

62-55-5

75.13

C2H5NS

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (1331.03 mM)

CC(N)=S

——

(-20℃)

With Ice Pack

≥ 2 years